Tavros Therapeutics, Inc.

Bayer has asked investors for patience as the conglomerate works its way through various challenges across its pharmaceuticals, crop science and consumer health businesses, and in 2024 pharma showed t

Founded eight years ago, Bayer subsidiary BlueRock Therapeutics is now putting the final touches to the late-stage program for bemdaneprocel, its closely watched investigational cell therapy for Parki

Nearly three and a half years after being bought by Bayer, Vividion Therapeutics has itself hit the acquisition trial to buy the US precision oncology platform company Tavros Therapeutics. Vividion sa

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A